The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
 
Matthew A. Gubens
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Nektar; Pfizer
Research Funding - Abbvie (Inst); Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche
 
Lecia V. Sequist
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
James Stevenson
Research Funding - Merck Sharp & Dohme (Inst); Verastem (Inst)
 
Steven Francis Powell
Research Funding - Merck
 
Liza Cosca Villaruz
Research Funding - Bristol-Myers Squibb; Merck
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer/Onyx; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Millennium
Research Funding - Advantagene (Inst); Ariad (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - AVEO (Inst); Bayer (Inst); Corvus Pharmaceuticals (Inst); Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Plexxikon (Inst); Symphony Evolution (Inst); Tesaro (Inst)
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
Research Funding - Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
 
Shadia Ibrahim Jalal
No Relationships to Disclose
 
Joseph Fiore
Employment - Merck
 
Joy Yang Ge
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Harry Raftopoulos
Employment - Merck
 
Leena Gandhi
Honoraria - Merck
Consulting or Advisory Role - Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb